The U.S. Dept. of Justice said today that Abbott‘s (NYSE:ABT) Alere (NYSE:ALR) agreed to pay $33.2 million to resolve allegations that it knowingly sold unreliable point-of-care diagnostic devices, causing hospitals to submit false claim to Medicare, Medicaid and other federal healthcare programs.
The U.S. alleged that Alere sold materially unreliable Triage devices, which are designed to diagnose serious conditions like acute coronary syndrome and drug overdose, between Jan. 2006 and March 2012. The government claimed that Alere received an array of customer complaints regarding its Triage devices, notifying the company that certain devices produced results with the potential to create false positives and negatives.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!